AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca’s ongoing Phase II umbrella study, officially titled An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON), aims to evaluate new anti-cancer agents for patients with metastatic non-small cell lung cancer (NSCLC) who have not responded to previous treatments. The study is significant as it addresses the urgent need for novel therapies in this patient group.
The study tests various experimental drug combinations, including Durvalumab paired with other agents like Olaparib, AZD9150, and Vistusertib, among others. These combinations are designed to assess their efficacy, safety, and tolerability in treating NSCLC.
This interventional study is non-randomized with a parallel assignment model, and it is open-label, meaning both researchers and participants know which treatments are being administered. The primary purpose is to find effective treatments for NSCLC patients who have exhausted other options.
The study began on December 18, 2017, with its primary completion and estimated completion dates yet to be disclosed. The latest update was submitted on July 23, 2025, indicating ongoing progress.
This clinical update could potentially boost AstraZeneca’s stock performance and investor confidence, given the high demand for effective cancer treatments. The study’s outcomes may also influence the competitive landscape in the oncology sector.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.